Zhang Li, Yao Mengchu, Yan Wei, Liu Xiaoning, Jiang Baofei, Qian Zhaoye, Gao Yong, Lu Xiao-Jie, Chen Xiaofei, Wang Qi-Long
Department of Hematology.
Department of Clinical Oncology.
Int J Nanomedicine. 2017 Sep 11;12:6759-6769. doi: 10.2147/IJN.S142916. eCollection 2017.
Low toxicity and high efficacy are the key factors influencing the real-world clinical applications of nanomaterial-assisted drug delivery. In this study, novel hollow carbon spheres (HCSs) with narrow size distribution were developed. In addition to demonstrating their ease of synthesis for large-scale production, we also demonstrated in vitro that the HCSs possessed high drug-loading capacity, lower cell toxicity, and optimal drug release profile at low pH, similar to the pH in the tumor microenvironment. The HCSs also displayed excellent immunocompatibility and could rapidly distribute themselves in the cytoplasm to escape lysosomal clearance. More importantly, the HCSs could efficiently deliver doxorubicin (a representative chemotherapeutic drug) to tumor sites, which resulted in significant inhibition of tumor growth in an esophageal xenograft cancer model. This also prolonged the circulation time and altered the biodistribution of the drug. In conclusion, this study revealed a novel drug delivery system for targeted tumor therapy.
低毒性和高效能是影响纳米材料辅助药物递送在实际临床应用中的关键因素。在本研究中,开发了具有窄尺寸分布的新型中空碳球(HCSs)。除了证明它们易于合成以进行大规模生产外,我们还在体外证明了HCSs具有高载药能力、较低的细胞毒性以及在低pH值(类似于肿瘤微环境中的pH值)下的最佳药物释放曲线。HCSs还表现出优异的免疫相容性,并且可以迅速在细胞质中分布以逃避溶酶体清除。更重要的是,HCSs可以有效地将阿霉素(一种代表性的化疗药物)递送至肿瘤部位,这在食管异种移植癌模型中导致了肿瘤生长的显著抑制。这也延长了药物的循环时间并改变了药物的生物分布。总之,本研究揭示了一种用于靶向肿瘤治疗的新型药物递送系统。